CFB and prostate cancer: Since targeting Gβγ signaling inhibits the self-renewal activity and tumorigenicity of prostate cancer CSCs, we tested whether blocking Gβγ signaling sensitizes prostate cancer cells to the chemotherapeutic agent, paclitaxel.